Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors - Trial NCT06346041
Access comprehensive clinical trial information for NCT06346041 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Neoplasms. Target enrollment is 19 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 1
Apr 12, 2024
Apr 01, 2026
Primary Outcome
Dose Limiting Toxicities (DLT),Incidence of adverse events and severe adverse events,MTD/MFD
Summary
This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or
 MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in
 patients with advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06346041
Non-Device Trial